Roche’s subcutaneous version of its multiple sclerosis (MS) med Ocrevus triumphed in a key late-stage study, likely setting up a new opportunity for the blockbuster drug.. The study, called ...

Notably, though, while subcutaneous injections are often preferable over IV injections, some people report they perceive IV infusions to be more effective than subcutaneous injections, making them ...

The FDA approved ocrelizumab and hyaluronidase-ocsq (Ocrevus Zunovo; Genentech), a twice-yearly subcutaneous injection, for relapsing multiple sclerosis (RMS) and primary progressive multiple ...

CHICAGO — An oral robotic pill may provide an alternative delivery method to subcutaneous injection for teriparatide and other biologics, according to a speaker at ENDO 2023. In findings from a ...

The FDA approved atezolizumab and hyaluronidase-tqjs for subcutaneous injection.The agent (Tecentriq Hybreza, Genentech) is the first subcutaneous anti-PD-L1 cancer immunotherapy approved in the ...